A Phase III, Open-label, Clinical Trial to Assess the Long Term Safety and Tolerability of MK-0653H in Japanese Patients With Hypercholesterolemia Who Have Inadequate LDL-C Control on Ezetimibe or Rosuvastatin Monotherapy

Trial Profile

A Phase III, Open-label, Clinical Trial to Assess the Long Term Safety and Tolerability of MK-0653H in Japanese Patients With Hypercholesterolemia Who Have Inadequate LDL-C Control on Ezetimibe or Rosuvastatin Monotherapy

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 29 Apr 2017

At a glance

  • Drugs Ezetimibe/rosuvastatin (Primary)
  • Indications Hypercholesterolaemia
  • Focus Adverse reactions
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 12 Apr 2017 Planned End Date changed from 1 Dec 2017 to 15 Dec 2017.
    • 12 Apr 2017 Planned primary completion date changed from 1 Dec 2017 to 15 Dec 2017.
    • 21 Nov 2016 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top